Literature DB >> 20112278

Human progenitor-derived endothelial cells vs. venous endothelial cells for vascular tissue engineering: an in vitro study.

Noélie B Thebaud1, Reine Bareille, Murielle Remy, Chantal Bourget, Richard Daculsi, Laurence Bordenave.   

Abstract

The isolation of endothelial progenitor cells from human peripheral blood generates a great hope in vascular tissue engineering because of particular benefit when compared with mature endothelial cells. We explored the capability of progenitor-derived endothelial cells (PDECs) to line fibrin and collagen scaffolds in comparison with human saphenous and umbilical cord vein endothelial cells (HSVECs and HUVECs): (a) in a static situation, allowing definition of the optimal cell culture conditions with different media and cell-seeding densities to check cell behaviour; (b) under shear stress conditions (flow chambers or tubular vascular constructs), allowing investigation of cell response and mRNA expression on both substrates by oligonucleotide microarray analysis and quantitative real-time PCR. Well characterized PDECs: (a) could not be expanded adequately with the usual mature ECs culture media; (b) were able to colonize and grow on fibrin glue; (c) exhibited higher resistance to oxidative stress than HSVECs and HUVECs; (d) withstood physiological shear stress when lining both substrates in flow chambers, and their gene expression was regulated; (e) colonized a collagen-impregnated vascular prosthesis and were able to sense mechanical forces. Our results provide an improved qualification of PDECs for vascular tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112278     DOI: 10.1002/term.261

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  7 in total

1.  Fibrin acts as biomimetic niche inducing both differentiation and stem cell marker expression of early human endothelial progenitor cells.

Authors:  M C Barsotti; A Magera; C Armani; F Chiellini; F Felice; D Dinucci; A M Piras; A Minnocci; R Solaro; G Soldani; A Balbarini; R Di Stefano
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

Review 2.  A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications.

Authors:  G P Fadini
Journal:  Diabetologia       Date:  2013-10-31       Impact factor: 10.122

3.  The use of total human bone marrow fraction in a direct three-dimensional expansion approach for bone tissue engineering applications: focus on angiogenesis and osteogenesis.

Authors:  Julien Guerrero; Hugo Oliveira; Sylvain Catros; Robin Siadous; Sidi-Mohammed Derkaoui; Reine Bareille; Didier Letourneur; Joëlle Amédée
Journal:  Tissue Eng Part A       Date:  2014-12-01       Impact factor: 3.845

4.  Layer-by-layer bioassembly of cellularized polylactic acid porous membranes for bone tissue engineering.

Authors:  Vera Guduric; Carole Metz; Robin Siadous; Reine Bareille; Riccardo Levato; Elisabeth Engel; Jean-Christophe Fricain; Raphaël Devillard; Ognjan Luzanin; Sylvain Catros
Journal:  J Mater Sci Mater Med       Date:  2017-04-06       Impact factor: 3.896

5.  Shear stress responses of adult blood outgrowth endothelial cells seeded on bioartificial tissue.

Authors:  Katherine A Ahmann; Sandra L Johnson; Robert P Hebbel; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2011-07-01       Impact factor: 3.845

6.  IQ domain GTPase-activating protein 1 is involved in shear stress-induced progenitor-derived endothelial cell alignment.

Authors:  Lila Rami; Patrick Auguste; Noélie B Thebaud; Reine Bareille; Richard Daculsi; Jean Ripoche; Laurence Bordenave
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

Review 7.  When Good Guys Turn Bad: Bone Marrow's and Hematopoietic Stem Cells' Role in the Pathobiology of Diabetic Complications.

Authors:  Maria Cristina Vinci; Elisa Gambini; Beatrice Bassetti; Stefano Genovese; Giulio Pompilio
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.